anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with chronic kidney disease (CKD) are at an increased cardiovascular risk compared with the general population, which is driven, at least in part, by mechanisms that are uniquely associated with kidney disease. In CKD, increased levels of oxidative stress and uraemic retention solutes, including urea and advanced glycation end products, enhance non-enzymatic post-translational modification events, such as protein oxidation, glycation, carbamylation and guanidinylation. Alterations in enzymatic post-translational modifications such as glycosylation, ubiquitination, acetylation and methylation are also detected in CKD. Post-translational modifications can alter the structure and function of proteins and lipoprotein particles, thereby affecting cellular processes. In CKD, evidence suggests that post-translationally modified proteins can contribute to inflammation, oxidative stress and fibrosis, and induce vascular damage or prothrombotic effects, which might contribute to CKD progression and/or increase cardiovascular risk in patients with CKD. Consequently, post-translational protein modifications prevalent in CKD might be useful as diagnostic biomarkers and indicators of disease activity that could be used to guide and evaluate therapeutic interventions, in addition to providing potential novel therapeutic targets.
Concentrated extract must be diluted with sterile diluent prior to first use on a patient for treatment or intradermal testing. All concentrates of allergenic extract are manufactured to assure high potency and therefore have the ability to cause serious local and systemic reactions, including death in sensitive patients 11. Patients should be informed of this risk and precautions should be discussed prior to initiating immunotherapy (see PRECAUTIONS below).   
Allergenic extract should be temporarily withheld from patients or the dose adjusted downward if any of the following conditions exist: 1) severe symptoms of rhinitis and/or asthma; 2) infection or flu accompanied by fever; 3) exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection.   
The dosage must be reduced when starting a patient on fresh standardized mite extract or when transferring a patient from non-standardized or modified extract to standardized extract, even though the labeled strength of the old and new vials may be the same. This is necessary due to a loss of extract potency during storage in the physician's office. The mite allergen content of old and new extract may be compared and adjusted by dosage reduction and/or dilution before the new extract is administered. The amount of new extract given should not exceed 25% of the last dose given from the old vial, assuming both extracts contain comparable amounts of mite allergen. Any evidence of a local or generalized reaction requires a reduction in dosage during the initial stages of immunotherapy, as well as during maintenance therapy.   
Beta-blocking drugs may make patients refractory to the usual dose of epinephrine, in the event epinephrine is required to treat an adverse allergic reaction.
Cesarean section is one of the most common surgeries performed today with over one million performed in the United States annually. Our institiution is a tertiary maternity hospital with approximately 3500 cesarean sections annually. A standardized set of guidelines known as Enhanced Recovery After Surgery (ERAS) has been used in a variety of surgical specialties, including colorectal, urologic, gynecologic, and hepatobiliary surgery. The adoption of ERAS guidelines for the obstetric population now offers evidence-based recommendations for postoperative care following cesarean delivery.

At our institution, due to large volume of cesarean section, we encounter a variety of postoperative complications. Institutional standard of care for preoperative, intraoperative and postoperative care has been applied by all providers. In light of recent positive evidence when ERAS protocol is applied, our team aimed to design a randomized controlled trial for comparison of maternal outcomes in ERAS and standard of care.
Systemic inflammation and innate immune activation are associated with COVID-19 disease severity. Knowledge gaps remain in the relationships between microbiome, inflammation and COVID-19 disease severity. To better characterise these associations, we performed 16SrDNA analysis of stool samples in COVID-19 subjects to explore diversity and taxanomic composition. We correlated these to host inflammatory profiles, derived from soluble plasma biomarkers measured by bead-based fluorescence and electrochemiluminescence immunoassays. Associations of microbial diversity and inflammatory biomarkers on maximal COVID-19 severity (mild, moderate v severe/critical) was explored using logistic regression and weighted gene correlation network analysis (WGCNA). Of 79 subjects, 58% were male and 88% were Caucasian with 36% experiencing mild disease, 22% moderate disease and 40% critical/severe COVID-19. Hierarchical clustering and principal component analysis (PCo) revealed distinct inflammatory clusters that were found to correlate with 4 modules of microbiome profiles. Modules 3 and 4 were associated with both older age and severe/critical disease outcomes. These modules were enriched in pathogenic and inflammatory bacteria that mapped to a pro-inflammatory biomarker cluster. In contrast, module 1 exhibited enrichment of anti-inflammatory bacteria, was associated with younger age and mild/moderate disease outcomes and mapped to a less-inflamed biomarker cluster. This study provides further insights into links between host microbiome, inflammatory responses to SARS-CoV-2 infection and clinical COVID-19 disease severity, suggesting a role for the microbiome in shaping distinct host inflammatory responses to infection.
The present invention relates to a trans-tumoral peptide (TPP), which specifically bonds with neuropilin, or a fused protein fused with the peptide, a small molecule drug, a nanoparticle, or a liposome. Moreover, the present invention provides a polynucleotide which codes the peptide, a recombinant vector including the same, a host cell which is transformed through the vector, and a method for producing a TPP using the same. Furthermore, the present invention relates to a pharmaceutical composition including the peptide or the fused protein, small molecule drug, nanoparticle, or liposome for treating, diagnosing, or preventing diseases related to cancer or angiogenesis. A fused antibody in which the TPP according to the present invention is fused with a C-terminal of an anticancer antibody medium chain invariant region (Fc) specifically bonds with neuropilin to be specifically accumulated in a tumor tissue and widen a cell gap of tumor vascular endothelial cells so that extravasation discharging is improved and penetration in tumor tissues is improved. Accordingly, remarkably improved in vivo tumor controlling activities are exhibited. In addition, a fused protein fused with the TPP according to the present invention inhibits angiogenesis functions among the functions of a neuropilin co-acceptor caused by neuropilin targeting, so that an effect in alleviating angiogenesis related diseases can be expected.
Disclosed is a new urethane polyacrylate having at least one terminal isocyanato acrylic pendent radical. Preferably the molecular chain within the acrylate caps has been extended with a polyhydroxy compound just before final end capping with isocyanato acrylic. The isocyanato acrylic is preferably isocyanato ethyl methacrylate and the urethane is diisocyanate capped polyether and the polyether radical is oxyalkylene. The method for producing the urethane polyacrylate involves end capping a polyol with diisocyanate yielding a reaction product with two reactive equivalents of isocyanate and then capping less than all of the isocyanate with a hydroxyacrylate, after which the remaining isocyanate is reacted with polyol to provide chain extension. The chain extending polyol is then capped with a isocyanato acrylic. Also disclosed is a new impression material for application to mammalian tissue and curing in contact therewith; the impression material including a free radical polymerizable resin, alkyl benzensulfonyl titanate, polymerization initiator, and filler; and a method of use.
Experiencing decline in both cognition and mobility is associated with a substantially higher dementia risk than cognitive decline only. Metabolites associated with both cognitive and mobility declines may be early predictors of dementia and reveal specific pathways to dementia. We analyzed data from 2450 participants initially free of dementia who had 613 metabolites measured in plasma in 1998-1999 (mean age = 75.2 ± 2.9 years old, 37.8% Black, 50% women) from the Health, Aging and Body Composition study. Dementia diagnosis was determined by race-specific decline in 3MS scores, medication use, and hospital records through 2014. Cognition and mobility were repeatedly measured using 3MS and a 20-m walking test up to 10 years, respectively. We examined metabolite associations with changes in 3MS (n = 2046) and gait speed (n = 2019) using multivariable linear regression adjusted for age, sex, race, and baseline performance and examined metabolite associations with dementia risk using Cox regression. During a mean follow-up of 9.3 years, 534 (21.8%) participants developed dementia. On average, 3MS declined 0.47/year and gait declined 0.04 m/sec/year. After covariate adjustment, 75 metabolites were associated with cognitive decline, and 111 metabolites were associated with gait decline (FDR-adjusted p < 0.05). Twenty-six metabolites were associated with both cognitive and gait declines. Eighteen of 26 metabolites were associated with dementia risk (p < 0.05), notably amino acids, glycerophospholipids (lysoPCs, PCs, PEs), and sphingolipids. Results remained similar after adjusting for cardiovascular disease or apolipoprotein E ɛ4 carrier status. During aging, metabolomic profiles of cognitive decline and mobility decline show distinct and shared signatures. Shared metabolomic profiles suggest that inflammation and deficits in mitochondria and the urea cycle in addition to the central nervous system may play key roles in both cognitive and mobility declines and predict dementia. Future studies are warranted to investigate longitudinal metabolite changes and metabolomic markers with dementia pathologies.
Prospective double-blinded trial of patients already implanted with SCS to determine which programming model best controls their back and or leg pain. Baseline visit is 2 weeks after implant. Baseline study data is collected, program #1 is started. The visit @ week 4 collects NRS, changes to program #2. The visit @ week 6 collect NRS, and starts program #3. The visit @ week 8 collects NRS. Subject chooses their preferred program from the previous 3 and uses that for the next 12 weeks. The visit @ week 20 collects NRS.
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a gel sustained-release preparation taking insoluble salt as a pH regulator, and a preparation method and application thereof. The gel sustained-release preparation taking the insoluble salt as the pH regulator is prepared by blending insoluble salt crystalline powder, an alkaline inclusion and a polymer solution. The preparation has injectable property, can be converted into gel state after being injected into organism, and realizes slow release of the inclusion at injection site. The insoluble salt reduces the solubility of the inclusion in the gel by adjusting the pH inside the gel, so that part of the inclusion is dispersed in the gel network in the form of crystals. The sudden release of the wrapping object from the gel is prevented in the early stage, and the indissolvable salt is gradually dissolved along with the accumulation of acidic degradation products of the gel in the later stage, so that the slow release of the wrapping object is realized. The technology can be applied to the fields of long-acting analgesia, medical cosmetology, tumor resistance and the like.
<P>PROBLEM TO BE SOLVED: To provide an acid dye complex having excellent coloring power, dissolution resistance, light resistance, chlorine resistance, etc., and excellent dispersibility in water and oil, a method for the production of the complex and a pigment composition compounded with the complex.  <P>SOLUTION: The acid dye laminate pigment is produced by covering a surface of a powder particle constituting the base with an acid dye inclusion clay mineral having a surface charge opposite to the charge of the base particle. The acid dye inclusion clay mineral contains a polybase and the acid dye intercalated between the layers of a water-swelling clay mineral. As an alternative, the acid dye laminate pigment is produced by laminating one or more layers of an acid dye inclusion clay mineral on the surface of the acid dye laminate pigment and a layer composed of an ionic molecule having a surface charge opposite to the charge of the acid dye inclusion clay mineral is present between the layers of the acid dye inclusion clay mineral. The polybase preferably has a quaternary ammonium base in the molecule. The acid dye inclusion clay mineral can be used as a water-based coloring agent.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
<P>PROBLEM TO BE SOLVED: To provide a medical drug such as an antihistamine drug comprising at least one chosen from an aminopropylidene derivative and a pharmacologically acceptable salt or hydrate thereof.  <P>SOLUTION: The aminopropylidene derivative has a strong histamine receptor antagonistic action. The compound shows low intracerebral migration, even when orally administered to a mouse and subjected to an intracerebral receptor binding test, so the compound has preferred properties in terms of alleviating adverse effects on the central nervous system, e.g. drowsiness. The aminopropylidene derivative is extremely useful as an active ingredient of a pharmaceutical composition such as a novel antihistamine drug causing few adverse effects on the central nervous system, such as drowsiness.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Breast engorgement as the swelling and distention of breast, which is one of the most common problems of postpartum of 3-8 days. At the same time, the congested blood vessels and tissue fluid will enter the surrounding tissues, resulting in the retention of tissue fluid and blood, resulting in interstitial fluid. In cases such as interstitial edema, the flow of milk is restricted.

There are many conservative treatments for relieving breast swelling. At present, there have been published studies on the application of ultrasound therapy and manual lymphatic drainage to breast problems during lactation. Previous studies have shown that manual lymphatic drainage and ultrasound therapy can significantly improve the pain, temperature, and firmness of breast engorgement. Manual lymphatic drainage and ultrasound therapy have been widely used in physical therapy, but there is little empirical evidence for manual lymphatic drainage on breast swelling. It is hoped that this empirical medical research method can be used to reduce the effect of breast pain caused by breast problems and improve breast milk. The purpose of this study was to examine whether manual lymphatic drainage and ultrasound therapy can improve breast pain, breast swelling, and increase the flow and volume of milk removed.
According to recent data, one in eight people in the world struggle with obesity. Obesity management is increasingly dependent on bariatric surgical interventions, as the combination of lifestyle modifications and pharmacotherapy could have a modest long-term effect. Surgery is recommended only for individuals whose body mass index (BMI) ≥ 40 kg/m2 and ≥ 35 kg/m2 in the presence of weight-related comorbidities. The most commonly performed procedures are sleeve gastrectomy and roux-en-Y gastric bypass. Pharmacokinetic and pharmacodynamic alterations occur as a result of the anatomical and physiological changes caused by surgery, which further differ depending on physicochemical drug factors and factors related to the dosage form. The following modifications are distinguished based on the type of bariatric surgery performed. Most bariatric patients have accompanying comorbidities, including dyslipidemia treated with hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins. Significant improvements in the lipid profile are observed early in the postoperative period. The data reported in this review on statin pharmacokinetic alterations have demonstrated substantial inter- and intravariability, making it difficult to adopt clear guidelines. Based on the current literature review, reducing the statin dose to the lowest effective with continuous monitoring is considered an optimal approach in clinical practice.
During this process, the clown will continue to distract the children by playing games and blowing foam balloons. During the procedure, the child's pain and anxiety score will be evaluated by both the researcher, the parent, and the child. After the procedure is completed, children will be taken out of the blood collection room and taken to the waiting area in the next room, and after being allowed to rest for 1-2 minutes, surveys will be administered to the children.
PCT No. PCT/JP96/01057 Sec. 371 Date Dec. 18, 1997 Sec. 102(e) Date Dec. 18, 1997 PCT Filed Apr. 18, 1996 PCT Pub. No. WO96/33233 PCT Pub. Date Oct. 24, 1996This invention provides a heterotelechelic oligomer or polymer which is represented by formula below: wherein R1 and R2 form an acetal, or, combined with each other, denote oxy (=O), p, m, n and q each denote a certain integer, L is a group which forms an ester, and Z denotes a certain functional group. This invention a so provides a process to produce the above oligomer or polymer by means of living polymeri-zation. Since this oligomer or polymer forms a high- molecular micelle which is stable in an aqueous solvent, said oligomer or polymer will be useful as a carrier for drug delivery.
For patients whose tumors express one (1) or more of these TAPAs (Sp17, ropporin, AKAP-4, PTTG1, Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1), whole blood will be obtained by phlebotomy and/or leukapheresis performed for generation of autologous DCs. Patient's DCs will be generated in Kiromic's Cell Processing GMP facility, according to established Standard Operating Procedures, and activated by pulsing/loading them with the TAPA(s) relevant for each particular patient. Patients will receive five (5) days of low-dose cyclophosphamide 5 to 7 days prior to each vaccination with TAPA-pulsed DCs to decrease Treg activity. Patients will also receive a single dose of topical Imiquimod cream after each vaccination. TAPA-pulsed DCs will be administered at a fixed dose of up to 1 X 107 DCs. DC vaccination schedule will be weekly via intradermal (ID) injections for a total of 3 vaccinations. Topical Imiquimod cream will also be administered once after the vaccination. Patients will be followed on a weekly basis (or more frequently if required) to evaluate treatment-related toxicity. Immune efficacy and anti-tumor responses will be evaluated per protocol specifications. Continuation and stopping rules for the study will be defined based on toxicity/tolerability (Phase I) and immune efficacy (Phase II).
PROBLEM TO BE SOLVED: To analyze a stomach electric signal in daily life by measuring an electric signal caused by the movement of a stomach and resolving it to frequency component by the group of filters consisting of plural band pass filters. SOLUTION: The stomach electric signal guided out from an electrode mounted on a human body 1 is amplified to a proper level by an amplifier 2 and converted to a digital signal by an A/D converter 3. The A/D-converted value is inputted to each filter of a filter group 4 consisting of the plural band pass filters to calculate a digital filter. The result of calculation is outputted to a D/A-converter 5 and its result is recorded in a multi-channel recorder 6. Instead of the converter 5 and the recorder 6, it is possible to arrange a printer to output. Then, the obtained calculation result is expressed directly or as a graph expressing the strength of amplitude extracted by each filter by a color scale to judge the change and fluctuation of the movement of the stomach based on it.
Tianeptine group (group T) patients will receive Tianeptine 12.5 mg (Stablon, Servier, France)with a sip of water one hour before induction of anesthesia and repeated every 8 hours for five days after surgery. The Tianeptine capsules will be given to patients by nurses blinded to the study. Neither the researcher allocating the participants, nor the assessing person knew the decoding of the groups in its relation to the allocation sequence. Data will be collected by a junior pain resident blinded to the study protocol.
This is a multicenter, bidirectional cohort study. Retrospective training cohort, retrospective validation cohort and prospective test cohort were designed.

Data of patients treated in the North Ward of Sun Yat-sen Memorial Hospital of Sun Yat-sen University from January 1, 2002 to August 31, 2023 were retrospectively collected for training cohort, and data of patients treated in the South ward of Sun Yat-sen Memorial Hospital of Sun Yat-sen University for internal validation cohort; Data on patients treated at external centers between January 1, 2002 and August 31, 2023 were retrospectively collected for external validation cohort. Data on patients admitted to Sun Yat-sen Memorial Hospital at Sun Yat-sen University after January 1, 2024 were prospectively collected for the test cohort. Patient data collected included: pathological images and report texts of breast puncture specimens before neoadjuvant chemotherapy, breast magnetic resonance images and report texts before neoadjuvant chemotherapy, postoperative pathological reports and clinical information, etc.. An artificial intelligence large language model based on multi-task and multi-modal data integration was established to accurately predict the efficacy of neoadjuvant chemotherapy for breast cancer, and its predictive efficacy was tested by retrospective validation cohort and prospective double-blind test cohort. The retrospective cohort of this study was followed up to collect clinical data, magnetic resonance imaging and reports, and surgical pathology reports of patients, etc.. When patients had disease recurrence, the DFS time of patients was recorded, and when patients did not have disease recurrence, the last follow-up time was recorded. Baseline data survey was completed during hospitalization of prospective cohort patients. Pathological reports of breast tumors surgically removed after neoadjuvant chemotherapy were obtained during follow-up, as well as the time of disease recurrence and the time of death of patients. Clinical information such as magnetic resonance imaging and reports were collected during follow-up. Follow-up until the end of the 2-year study.